A prospective phase II trial of EGCG in treatment of acute radiation-induced esophagitis for stage III lung cancer

Radiotherapy and Oncology

Volumn 114, Issue 3, 2015, Pages 351-356

  Zhao, Hanxi ^a   Xie, Peng ^a,b   Li, Xiaolin ^a   Zhu, Wanqi ^a   Sun, Xindong ^a   Sun, Xiaorong ^a   Chen, Xiaoting ^a   Xing, Ligang ^a   Yu, Jinming ^a  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Acute radiation induced esophagitis (ARIE); Epigallocatechin 3 gallate (EGCG); Phase II trial

Indexed keywords

ANTINEOPLASTIC AGENT; EPIGALLOCATECHIN GALLATE; CATECHIN;

ACUTE RADIATION INDUCED ESOPHAGITIS; ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CHEMORADIOTHERAPY; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; DYSPHAGIA; ESOPHAGUS PAIN; FEMALE; HUMAN; LUNG CANCER; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION INJURY; SCORING SYSTEM; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; ESOPHAGITIS; LUNG NEOPLASMS; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; QUALITY OF LIFE; RADIATION INJURIES;

ADULT; AGED; CATECHIN; ESOPHAGITIS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; QUALITY OF LIFE; RADIATION INJURIES;

EID: 84927575942     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2015.02.014     Document Type: Article

References (42)

1. R. Siegel, J. Ma, and Z. Zou Cancer statistics, 2014 CA Cancer J Clin 64 2014 9 29
2. Y. Segawa, K. Kiura, and N. Takigawa Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007 J Clin Oncol 28 2010 3299 3306
3. P. Fournel, G. Robinet, and P. Thomas Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study J Clin Oncol 23 2005 5910 5917
4. F.Y. Feng, H.M. Kim, and T.H. Lyden Intensity-modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal cancer: clinical and functional results J Clin Oncol 28 2010 2732 2738
5. J.L. Guerra, D. Gomez, and Q. Wei Association between single nucleotide polymorphisms of the transforming growth factor beta1 gene and the risk of severe radiation esophagitis in patients with lung cancer Radiother Oncol 105 2012 299 304
6. J. Rose, G. Rodrigues, and B. Yaremko Systematic review of dose-volume parameters in the prediction of esophagitis in thoracic radiotherapy Radiother Oncol 91 2009 282 287
7. T. Xu, Z. Liao, and M.S. O'Reilly Serum inflammatory miRNAs predict radiation esophagitis in patients receiving definitive radiochemotherapy for non-small cell lung cancer Radiother Oncol 113 2014 379 384
8. W.L. McGinnis, C.L. Loprinzi, and S.J. Buskirk Placebo-controlled trial of sucralfate for inhibiting radiation-induced esophagitis J Clin Oncol 15 1997 1239 1243
9. M.L. Hensley, K.L. Hagerty, and T. Kewalramani American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants J Clin Oncol 27 2009 127 145
10. M.A. Hildebrandt, R. Komaki, and Z. Liao Genetic variants in inflammation-related genes are associated with radiation-induced toxicity following treatment for non-small cell lung cancer PLoS One 5 2010 e12402
11. A. Hsu, R.S. Bruno, and C.V. Lohr Dietary soy and tea mitigate chronic inflammation and prostate cancer via NFkappaB pathway in the Noble rat model J Nutr Biochem 22 2011 502 510
12. F. Wu, H. Sun, and T. Kluz Epigallocatechin-3-gallate (EGCG) protects against chromate-induced toxicity in vitro Toxicol Appl Pharmacol 258 2012 166 175
13. Y.D. Jung, and L.M. Ellis Inhibition of tumour invasion and angiogenesis by epigallocatechin gallate (EGCG), a major component of green tea Int J Exp Pathol 82 2001 309 316
14. P.Y. Tay, C.P. Tan, and F. Abas Assessment of extraction parameters on antioxidant capacity, polyphenol content, epigallocatechin gallate (EGCG), epicatechin gallate (ECG) and iriflophenone 3-C-beta-glucoside of agarwood (Aquilaria crassna) young leaves Molecules 19 2014 12304 12319
15. H. Fujiki, M. Suganuma, and S. Okabe Cancer inhibition by green tea Mutat Res 402 1998 307 310
16. G. Nie, Y. Cao, and B. Zhao Protective effects of green tea polyphenols and their major component, (-)-epigallocatechin-3-gallate (EGCG), on 6-hydroxydopamine-induced apoptosis in PC12 cells Redox Rep 7 2002 171 177
17. H. Zhao, W. Zhu, and P. Xie A phase I study of concurrent chemotherapy and thoracic radiotherapy with oral epigallocatechin-3-gallate protection in patients with locally advanced stage III non-small-cell lung cancer Radiother Oncol 110 2014 132 136
18. Z. An, Y. Qi, and D. Huang EGCG inhibits Cd(2+)-induced apoptosis through scavenging ROS rather than chelating Cd(2+) in HL-7702 cells Toxicol Mech Methods 24 2014 259 267
19. J. Nijkamp, M. Rossi, and J. Lebesque Relating acute esophagitis to radiotherapy dose using FDG-PET in concurrent chemo-radiotherapy for locally advanced non-small cell lung cancer Radiother Oncol 106 2013 118 123
20. A. Auperin, C. Le Pechoux, and E. Rolland Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer J Clin Oncol 28 2010 2181 2190
21. H. Choy, K. LaPorte, and E. Knill-Selby Esophagitis in combined modality therapy for locally advanced non-small cell lung cancer Semin Radiat Oncol 9 1999 90 96
22. J. Belderbos, W. Heemsbergen, and M. Hoogeman Acute esophageal toxicity in non-small cell lung cancer patients after high dose conformal radiotherapy Radiother Oncol 75 2005 157 164
23. K. Takeda, K. Nemoto, and H. Saito Dosimetric correlations of acute esophagitis in lung cancer patients treated with radiotherapy Int J Radiat Oncol Biol Phys 62 2005 626 629
24. A.J. Wu, E. Williams, and A. Modh Dosimetric predictors of esophageal toxicity after stereotactic body radiotherapy for central lung tumors Radiother Oncol 2014
25. C. Tang, Z. Liao, and Y. Zhuang Acute phase response before treatment predicts radiation esophagitis in non-small cell lung cancer Radiother Oncol 110 2014 493 498
26. M. Feng, D.E. Smith, and D.P. Normolle A phase I clinical and pharmacology study using amifostine as a radioprotector in dose-escalated whole liver radiation therapy Int J Radiat Oncol Biol Phys 83 2012 1441 1447
27. R.P. Hill, A. Zaidi, and J. Mahmood Investigations into the role of inflammation in normal tissue response to irradiation Radiother Oncol 101 2011 73 79
28. B. Movsas, C. Scott, and C. Langer Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01 J Clin Oncol 23 2005 2145 2154
29. S.T. Sonis, L.S. Elting, and D. Keefe Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients Cancer 100 2004 1995 2025
30. S.C. Formenti, and S. Demaria Combining radiotherapy and cancer immunotherapy: a paradigm shift J Natl Cancer Inst 105 2013 256 265
31. F.S. Hodi, S.J. O'Day, and D.F. McDermott Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723
32. J.D. Brody, W.Z. Ai, and D.K. Czerwinski In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study J Clin Oncol 28 2010 4324 4332
33. M. Pae, Z. Ren, and M. Meydani Epigallocatechin-3-gallate directly suppresses T cell proliferation through impaired IL-2 utilization and cell cycle progression J Nutr 140 2010 1509 1515
34. D. Wu, J. Wang, and M. Pae Green tea EGCG, T cells, and T cell-mediated autoimmune diseases Mol Aspects Med 33 2012 107 118
35. I. Hauber, H. Hohenberg, and B. Holstermann The main green tea polyphenol epigallocatechin-3-gallate counteracts semen-mediated enhancement of HIV infection Proc Natl Acad Sci U S A 106 2009 9033 9038
36. D.E. Ehrnhoefer, J. Bieschke, and A. Boeddrich EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers Nat Struct Mol Biol 15 2008 558 566
37. W. Hunstein Epigallocathechin-3-gallate in AL amyloidosis: a new therapeutic option? Blood 110 2007 2216
38. N. Ferreira, M.J. Saraiva, and M.R. Almeida Natural polyphenols inhibit different steps of the process of transthyretin (TTR) amyloid fibril formation FEBS Lett 585 2011 2424 2430
39. J. Bieschke, J. Russ, and R.P. Friedrich EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity Proc Natl Acad Sci U S A 107 2010 7710 7715
40. F.L. Palhano, J. Lee, and N.P. Grimster Toward the molecular mechanism(s) by which EGCG treatment remodels mature amyloid fibrils J Am Chem Soc 135 2013 7503 7510
41. Y. Cao, and R. Cao Angiogenesis inhibited by drinking tea Nature 398 1999 381
42. B. Groselj, M. Kerr, and A.E. Kiltie Radiosensitisation of bladder cancer cells by panobinostat is modulated by Ku80 expression Radiother Oncol 108 2013 429 433